Bank of New York Mellon’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.6M | Buy |
1,015,182
+101,093
| +11% | +$1.39M | ﹤0.01% | 1710 |
|
|
2026
Q1 | $11.4M | Buy |
914,089
+418,241
| +84% | +$5.62M | ﹤0.01% | 1868 |
|
|
2025
Q4 | $6.25M | Sell |
495,848
-104,355
| -17% | -$1.19M | ﹤0.01% | 2193 |
|
|
2025
Q3 | $6.01M | Buy |
600,203
+7,382
| +1% | +$66.3K | ﹤0.01% | 2213 |
|
|
2025
Q2 | $4.8M | Sell |
592,821
-5,568
| -0.9% | -$42K | ﹤0.01% | 2285 |
|
|
2025
Q1 | $5.01M | Sell |
598,389
-25,449
| -4% | -$212K | ﹤0.01% | 2219 |
|
|
2024
Q4 | $4.94M | Sell |
623,838
-894
| -0.1% | -$7.5K | ﹤0.01% | 2304 |
|
|
2024
Q3 | $5.2M | Sell |
624,732
-126,671
| -17% | -$991K | ﹤0.01% | 2275 |
|
|
2024
Q2 | $4.77M | Buy |
751,403
+128,772
| +21% | +$817K | ﹤0.01% | 2371 |
|
|
2024
Q1 | $3.77M | Sell |
622,631
-12,883
| -2% | -$72.6K | ﹤0.01% | 2452 |
|
|
2023
Q4 | $3.86M | Sell |
635,514
-52,848
| -8% | -$235K | ﹤0.01% | 2495 |
|
|
2023
Q3 | $2.9M | Buy |
688,362
+60,024
| +10% | +$224K | ﹤0.01% | 2592 |
|
|
2023
Q2 | $1.95M | Buy |
628,338
+165,137
| +36% | +$352K | ﹤0.01% | 2853 |
|
|
2023
Q1 | $644K | Sell |
463,201
-24,162
| -5% | -$48.1K | ﹤0.01% | 3355 |
|
|
2022
Q4 | $970K | Sell |
487,363
-100,493
| -17% | -$225K | ﹤0.01% | 3206 |
|
|
2022
Q3 | $1.19M | Buy |
587,856
+48,526
| +9% | +$136K | ﹤0.01% | 3118 |
|
|
2022
Q2 | $1.72M | Sell |
539,330
-27,007
| -5% | -$97.8K | ﹤0.01% | 2918 |
|
|
2022
Q1 | $2.36M | Buy |
566,337
+6,097
| +1% | +$27K | ﹤0.01% | 2836 |
|
|
2021
Q4 | $2.68M | Sell |
560,240
-24,603
| -4% | -$123K | ﹤0.01% | 2813 |
|
|
2021
Q3 | $3.12M | Buy |
584,843
+31,095
| +6% | +$157K | ﹤0.01% | 2748 |
|
|
2021
Q2 | $2.84M | Sell |
553,748
-85,795
| -13% | -$488K | ﹤0.01% | 2784 |
|
|
2021
Q1 | $4.3M | Sell |
639,543
-135,277
| -17% | -$750K | ﹤0.01% | 2505 |
|
|
2020
Q4 | $3.54M | Sell |
774,820
-223,226
| -22% | -$989K | ﹤0.01% | 2525 |
|
|
2020
Q3 | $3.87M | Sell |
998,046
-54,726
| -5% | -$234K | ﹤0.01% | 2352 |
|
|
2020
Q2 | $5.01M | Sell |
1,052,772
-200,237
| -16% | -$825K | ﹤0.01% | 2205 |
|
|
2020
Q1 | $4.36M | Sell |
1,253,009
-69,407
| -5% | -$294K | ﹤0.01% | 2140 |
|
|
2019
Q4 | $6.37M | Buy |
1,322,416
+787,166
| +147% | +$2.74M | ﹤0.01% | 2216 |
|
|
2019
Q3 | $1.55M | Buy |
535,250
+33,842
| +7% | +$118K | ﹤0.01% | 2895 |
|
|
2019
Q2 | $3.6M | Buy |
501,408
+15,435
| +3% | +$158K | ﹤0.01% | 2493 |
|
|
2019
Q1 | $6.89M | Buy |
485,973
+45,174
| +10% | +$597K | ﹤0.01% | 2179 |
|
|
2018
Q4 | $5.96M | Sell |
440,799
-53,736
| -11% | -$968K | ﹤0.01% | 2189 |
|
|
2018
Q3 | $11M | Buy |
494,535
+27,206
| +6% | +$573K | ﹤0.01% | 1964 |
|
|
2018
Q2 | $7.67M | Buy |
+467,329
| New | +$8.2M | ﹤0.01% | 2167 |
|
Other funds holding AMRX
WW
PCM
PFC
CAM
Bank of New York Mellon's AMRX Position: Q2 2026 in Review
Bank of New York Mellon increased its Amneal Pharmaceuticals (AMRX) stake by 11% in Q2 2026, buying an estimated $1.39M and bringing the position to 1,015,182 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1710.
Bank of New York Mellon first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. 136 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Bank of New York Mellon held 1,015,182 shares of Amneal Pharmaceuticals worth $17.6M as of Q2 2026.
- Bank of New York Mellon bought 101,093 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
- Amneal Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1710 holding.
- Bank of New York Mellon first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 136 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.